Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,742 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Isaka H, Hagio K, Shimomura A, Okumura Y, Futamura M, Shimokawa M, Takano T. Yokoe T, et al. Among authors: okumura y. Breast Cancer. 2021 May;28(3):581-591. doi: 10.1007/s12282-020-01192-y. Epub 2021 Jan 2. Breast Cancer. 2021. PMID: 33389616 Free PMC article.
Thrombocytopenia Caused by Dexamethasone in a Patient with Colorectal Cancer.
Taguchi R, Tsuchihashi K, Okumura Y, Nakano M, Yoshihiro T, Ohmura H, Tsuruta N, Hanamura F, Yamaguchi K, Ito M, Ariyama H, Kusaba H, Akashi K, Baba E. Taguchi R, et al. Among authors: okumura y. Intern Med. 2020;59(20):2571-2575. doi: 10.2169/internalmedicine.4785-20. Epub 2020 Oct 15. Intern Med. 2020. PMID: 33055471 Free PMC article.
Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer.
Masuda T, Ueo H, Okumura Y, Kai Y, Ando Y, Masuguchi K, Kitagawa M, Kitagawa A, Hayashi N, Tsuruda Y, Hisamatsu Y, Suehiro S, Ohmura H, Fujiyoshi K, Tanaka F, Mimori K. Masuda T, et al. Among authors: okumura y. Cancer Genomics Proteomics. 2023 Mar-Apr;20(2):182-194. doi: 10.21873/cgp.20373. Cancer Genomics Proteomics. 2023. PMID: 36870689 Free PMC article.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Ito M, Okumura Y, Nio K, Baba E, Ozaki Y, Nishio H, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Tsuchihashi K. Ito M, et al. Among authors: okumura y. Int J Clin Oncol. 2024 Jun;29(6):689-699. doi: 10.1007/s10147-024-02502-6. Epub 2024 Apr 5. Int J Clin Oncol. 2024. PMID: 38578596
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Tsuchihashi K, Ito M, Okumura Y, Nio K, Ozaki Y, Nishio H, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Baba E. Tsuchihashi K, et al. Among authors: okumura y. Int J Clin Oncol. 2024 Jun;29(6):700-705. doi: 10.1007/s10147-024-02541-z. Epub 2024 May 2. Int J Clin Oncol. 2024. PMID: 38696053
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, Nakanishi K, Sakai H, Tsukamoto S, Komine K, Yasuda Y, Kato T, Fujiwara Y, Koyama T, Kitamura H, Kuwabara T, Yonezawa A, Okumura Y, Yakushijin K, Nozawa K, Goto H, Matsubara T, Hoshino J, Yanagita M; Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022. Ando Y, et al. Among authors: okumura y. Int J Clin Oncol. 2023 Oct;28(10):1315-1332. doi: 10.1007/s10147-023-02382-2. Epub 2023 Jul 16. Int J Clin Oncol. 2023. PMID: 37453935
A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site.
Nishikawa K, Hironaka S, Inagaki T, Komori A, Otsu S, Mitsugi K, Makiyama A, Watanabe K, Tamura S, Okumura Y, Kusaba H, Esaki T, Baba E, Shirao K. Nishikawa K, et al. Among authors: okumura y. Jpn J Clin Oncol. 2022 Dec 5;52(12):1416-1422. doi: 10.1093/jjco/hyac143. Jpn J Clin Oncol. 2022. PMID: 36047806 Review.
1,742 results